{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:27Z","timestamp":1740107427625,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T00:00:00Z","timestamp":1477612800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00280-016-3182-8","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T11:44:03Z","timestamp":1477655043000},"page":"1237-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma"],"prefix":"10.1007","volume":"78","author":[{"given":"Chaitali","family":"Passey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Darbenzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"3182_CR1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s002510000274","volume":"52","author":"KS Boles","year":"2001","unstructured":"Boles KS, Mathew PA (2001) Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics 52:302\u2013307","journal-title":"Immunogenetics"},{"key":"3182_CR2","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775\u20132784","journal-title":"Clin Cancer Res"},{"key":"3182_CR3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329\u20131337","journal-title":"Blood"},{"key":"3182_CR4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","volume":"62","author":"SM Collins","year":"2013","unstructured":"Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr (2013) Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62:1841\u20131849","journal-title":"Cancer Immunol Immunother"},{"key":"3182_CR5","unstructured":"Food and Drug Administration (2005) Guidance for industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073153.pdf . Accessed 2 June 2016"},{"key":"3182_CR6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","volume":"89","author":"YG Yap","year":"2003","unstructured":"Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89:1363\u20131372","journal-title":"Heart"},{"key":"3182_CR7","unstructured":"ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) Working Group (2005) The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14. Step 4 version. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf . Accessed 2 June 2016"},{"key":"3182_CR8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/tx800035b","volume":"21","author":"JS Mitcheson","year":"2008","unstructured":"Mitcheson JS (2008) hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol 21:1005\u20131010","journal-title":"Chem Res Toxicol"},{"key":"3182_CR9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463\u2013469","journal-title":"Nature"},{"key":"3182_CR10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2010.07.001","volume":"160","author":"I Rodriguez","year":"2010","unstructured":"Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK (2010) Electrocardiographic assessment for therapeutic proteins\u2013scientific discussion. Am Heart J 160:627\u2013634","journal-title":"Am Heart J"},{"key":"3182_CR11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bcp.12477","volume":"79","author":"RR Shah","year":"2015","unstructured":"Shah RR, Morganroth J, Kleiman RB (2015) ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies. Br J Clin Pharmacol 79:456\u2013464","journal-title":"Br J Clin Pharmacol"},{"key":"3182_CR12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vascn.2008.04.001","volume":"58","author":"HM Vargas","year":"2008","unstructured":"Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harmer AR, Heath B, Hoffmann P, Lagrutta A, Leishman D, McMahon N, Mittelstadt S, Polonchuk L, Pugsley MK, Salata JJ, Valentin JP (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58:72\u201376","journal-title":"J Pharmacol Toxicol Methods"},{"key":"3182_CR13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u2013631","journal-title":"N Engl J Med"},{"key":"3182_CR14","unstructured":"Food and Drug Administration (2004) Decadron\u00ae (dexamethasone tablets, USP). NDA 11-664-S-062. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/11664slr062_decadron_lbl.pdf . Accessed 25 Apr 2016"},{"key":"3182_CR15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/jama.1972.03200250042011","volume":"221","author":"GB Schmidt","year":"1972","unstructured":"Schmidt GB, Meier MA, Sadove MS (1972) Sudden appearance of cardiac arrhythmias after dexamethasone. JAMA 221:1402\u20131404","journal-title":"JAMA"},{"key":"3182_CR16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.hrcr.2015.07.010","volume":"2","author":"JR Winterfield","year":"2016","unstructured":"Winterfield JR, Milan DJ (2016) Dexamethasone suppresses long QT phenotype in patient with acute promyelocytic leukemia (APL) treated with arsenic. Heart Rhythm Case Rep 2:280\u2013282","journal-title":"Heart Rhythm Case Rep"},{"key":"3182_CR17","unstructured":"Food and Drug Administration (2016) REVLIMID\u00ae prescribing information. http:\/\/www.revlimid.com\/wp-content\/uploads\/full-prescribing-information.pdf . Accessed 2 June 2016"},{"key":"3182_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12081","volume":"113","author":"N Chen","year":"2013","unstructured":"Chen N, Ye Y, Liu L, Reyes J, Assaf MS, Kasserra C, Zhou S, Palmisano M (2013) Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol 113:179\u2013186","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3182_CR19","unstructured":"ClinicalTrials.gov (2015) Biomarker study of elotuzumab in high risk smoldering myeloma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01441973 . Accessed 25 Apr 2016"},{"key":"3182_CR20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"key":"3182_CR21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121\u20131127","journal-title":"Leukemia"},{"key":"3182_CR22","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/0091270009341184","volume":"49","author":"S Rohatagi","year":"2009","unstructured":"Rohatagi S, Carrothers TJ, Kuwabara-Wagg J, Khariton T (2009) Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. J Clin Pharmacol 49:1284\u20131296","journal-title":"J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3182-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T22:21:02Z","timestamp":1498342862000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3182-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,28]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3182"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3182-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2016,10,28]]}}}